Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This
phase II trial is studying how well erlotinib works in treating patients with malignant
mesothelioma of the lung